1. Home
  2. Q vs INSM Comparison

Q vs INSM Comparison

Compare Q & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Qnity Electronics Inc.

Q

Qnity Electronics Inc.

SELL

Current Price

$114.91

Market Cap

26.4B

Sector

Technology

ML Signal

SELL

Logo Insmed Incorporated

INSM

Insmed Incorporated

SELL

Current Price

$123.43

Market Cap

22.4B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
Q
INSM
Founded
2024
1988
Country
United States
United States
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
26.4B
22.4B
IPO Year
2025
2000

Fundamental Metrics

Financial Performance
Metric
Q
INSM
Price
$114.91
$123.43
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
10
24
Target Price
$173.30
★ $194.18
AVG Volume (30 Days)
1.9M
★ 3.5M
Earning Date
11-04-2026
10-29-2026
Dividend Yield
★ 0.27%
N/A
EPS Growth
★ N/A
N/A
EPS
★ 2.18
N/A
Revenue
★ $4,754,000,000.00
N/A
Revenue This Year
$22.21
$206.94
Revenue Next Year
$11.89
$60.77
P/E Ratio
$54.41
★ N/A
Revenue Growth
★ 9.67
N/A
52 Week Low
$72.81
$90.39
52 Week High
$177.28
$212.75

Technical Indicators

Market Signals
Indicator
Q
INSM
Relative Strength Index (RSI) 44.61 67.58
Support Level $108.06 $119.23
Resistance Level $123.10 $130.83
Average True Range (ATR) 5.87 5.24
MACD 0.28 2.32
Stochastic Oscillator 30.31 96.10

Price Performance

Historical Comparison
Q
INSM

About Q Qnity Electronics Inc.

Qnity is a specialty chemicals company created in 2025 after being spun off from DuPont. It sells chemicals and materials to the semiconductor industry, which generates the majority of sales, and also the electronics industry. Qnity specializes in materials science, including supplying key materials required to manufacture semiconductors and interconnected devices.

About INSM Insmed Incorporated

Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.

Share on Social Networks: